Cansino Biologics Inc - Asset Resilience Ratio
Cansino Biologics Inc (688185) has an Asset Resilience Ratio of 19.00% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of Cansino Biologics Inc for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Cansino Biologics Inc's Asset Resilience Ratio has changed over time. See 688185 book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Cansino Biologics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 688185 market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.39 Billion | 19.0% |
| Total Liquid Assets | CN¥1.39 Billion | 19.00% |
Asset Resilience Insights
- Good Liquidity Position: Cansino Biologics Inc maintains a healthy 19.00% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Cansino Biologics Inc Industry Peers by Asset Resilience Ratio
Compare Cansino Biologics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521 |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Emcure Pharmaceuticals Ltd
NSE:EMCURE |
Drug Manufacturers - Specialty & Generic | 1.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538 |
Drug Manufacturers - Specialty & Generic | 2.69% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 20.24% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
Annual Asset Resilience Ratio for Cansino Biologics Inc (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Cansino Biologics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 20.58% | CN¥1.64 Billion ≈ $239.84 Million |
CN¥7.96 Billion ≈ $1.17 Billion |
-1.66pp |
| 2023-12-31 | 22.25% | CN¥2.07 Billion ≈ $303.34 Million |
CN¥9.32 Billion ≈ $1.36 Billion |
-0.01pp |
| 2022-12-31 | 22.25% | CN¥2.55 Billion ≈ $373.43 Million |
CN¥11.47 Billion ≈ $1.68 Billion |
+2.66pp |
| 2021-12-31 | 19.59% | CN¥2.33 Billion ≈ $340.37 Million |
CN¥11.87 Billion ≈ $1.74 Billion |
+9.71pp |
| 2020-12-31 | 9.88% | CN¥666.64 Million ≈ $97.55 Million |
CN¥6.75 Billion ≈ $987.46 Million |
-21.07pp |
| 2019-12-31 | 30.95% | CN¥552.34 Million ≈ $80.83 Million |
CN¥1.78 Billion ≈ $261.13 Million |
+13.36pp |
| 2018-12-31 | 17.59% | CN¥140.00 Million ≈ $20.49 Million |
CN¥795.88 Million ≈ $116.46 Million |
-28.88pp |
| 2017-12-31 | 46.47% | CN¥402.64 Million ≈ $58.92 Million |
CN¥866.36 Million ≈ $126.78 Million |
+17.66pp |
| 2016-12-31 | 28.82% | CN¥94.00 Million ≈ $13.76 Million |
CN¥326.17 Million ≈ $47.73 Million |
-- |
About Cansino Biologics Inc
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are i… Read more